Satellos Bioscience Inc.
MSCL.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.36M | -6.63M | -4.41M | -5.12M | -4.80M |
| Total Depreciation and Amortization | 8.60K | 2.20K | 2.20K | 1.50K | 1.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -518.60K | 3.17M | 371.20K | 21.50K | 2.17M |
| Change in Net Operating Assets | -705.80K | 256.60K | -97.90K | -187.70K | 778.40K |
| Cash from Operations | -5.58M | -3.21M | -4.14M | -5.29M | -1.85M |
| Capital Expenditure | 0.00 | 0.00 | -2.90K | -1.50K | -700.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -8.30M | 12.98M | 1.72M | -1.56M | -12.88M |
| Cash from Investing | -8.30M | 12.98M | 1.72M | -1.56M | -12.88M |
| Total Debt Issued | -- | -- | -- | -- | 140.00K |
| Total Debt Repaid | -- | -- | -- | -- | -237.00K |
| Issuance of Common Stock | 43.40M | 221.00K | 16.00K | -- | 2.69M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 9.85M | -- | -- | -- | -3.19M |
| Cash from Financing | 38.04M | 162.00K | 11.70K | -- | -444.00K |
| Foreign Exchange rate Adjustments | 297.90K | 31.50K | 4.40K | 206.20K | -1.14M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.46M | 9.97M | -2.40M | -6.64M | -16.31M |
